Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

US-based cancer therapy developers Cullinan Oncology and PDI Therapeutics have launched a new company called Cullinan Mica with $26m from a series A round that included Cullinan Oncology itself. Cullinan Oncology was joined by Avalon Ventures, the venture capital firm that formed PDI in 2015 in partnership with pharmaceutical firm GlaxoSmithKline, as well as Bregua…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.